Supernus Pharmaceuticals Inc

S49

Company Profile

  • Business description

    Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

  • Contact

    9715 Key West Avenue
    RockvilleMD20850
    USA

    T: +1 301 838-2500

    E: [email protected]

    https://www.supernus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    778

Stocks News & Analysis

stocks

This ASX miner is the cheapest in our iron ore coverage

High debt levels and low commodity prices were a concern, but agreed sell-downs and a ramp-up of key operations should help.
stocks

Apple names new CEO as Tim Cook steps aside after 15 years

John Ternus, Apple’s hardware chief, will take up the role in September.
stocks

Updating our commodity price assumptions

Our view as China’s steel production drops.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,074.4050.80-0.56%
CAC 408,209.3326.38-0.32%
DAX 4024,258.0212.85-0.05%
Dow JONES (US)49,149.38293.18-0.59%
FTSE 10010,497.870.22-0.00%
HKSE26,163.24324.24-1.22%
NASDAQ24,259.96144.43-0.59%
Nikkei 22559,585.86236.690.40%
NZX 50 Index12,945.6013.270.10%
S&P 5007,064.0145.13-0.63%
S&P/ASX 2008,843.6053.20-0.60%
SSE Composite Index4,106.2621.180.52%

Market Movers